Award
National Institute on Drug Abuse 11255601
Preclinical efficacy of AST-004 as a treatment for substance use disorder
Recipient
Astrocyte Pharmaceuticals, Inc., University of Texas San Antonio, Oklahoma Medical Research Foundation
Award Amount
$399,680.00
Ceiling
$399,680.00
Awarded
July 07, 2026
Identifier
11255601
Award for preclinical research on AST-004 as a treatment for substance use disorder, funded by the National Institute on Drug Abuse with an award amount of $399,680.
Description
The project aims to evaluate the efficacy of AST-004 in treating substance use disorder, focusing on cocaine and methamphetamine self-administration in rodent models. The project involves collaboration between Astrocyte Pharmaceuticals, Inc., the University of Texas San Antonio, and the Oklahoma Medical Research Foundation. Future steps include Phase II clinical trials and expanded preclinical testing.